Crescent Biopharma's Strategic Participation in Investor Conferences
Crescent Biopharma Inc. (Nasdaq: CBIO) is positioning itself at the forefront of oncology advancements. The company, dedicated to bringing innovative therapies to cancer patients, has recently announced its management team will be actively participating in several significant investor conferences throughout November. These presentations aim to enhance investor relations and promote awareness of its promising pipeline.
Highlighting Key Events in November
Guggenheim Annual Healthcare Innovation Conference
Kicking off the series of events, Crescent will be engaging in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 at 8:00 a.m. ET in Boston. This platform will provide an incredible opportunity for the management team to discuss the company’s groundbreaking strategies, future directions, and innovations that aim to transform cancer treatment.
Stifel 2025 Healthcare Conference
Following the Guggenheim conference, Crescent will continue its outreach at the Stifel 2025 Healthcare Conference on November 12 at 1:20 p.m. ET in New York. This gathering is known for facilitating discussions amongst investors, analysts, and healthcare innovators alike, making it a pivotal moment for Crescent to highlight its mission and vision.
Jefferies Global Healthcare Conference
The month will culminate with Crescent's participation in the Jefferies Global Healthcare Conference, where a fireside chat will occur on November 19 at 9:30 a.m. GMT (4:30 a.m. ET) in London. This global stage will allow Crescent to reach wider audiences, sharing insights into their development pipeline and therapeutic approaches.
Webcasts and Replays for Investors
For those interested in tuning into these discussions, Crescent will provide live webcasts of each presentation via its Investors section on the company’s official website. In an effort to maintain transparency and keep stakeholders informed, recordings of these sessions will also be accessible for a period of 90 days after each event.
About Crescent Biopharma
The vision of Crescent Biopharma is to emerge as a leader in oncology by developing the next generation of cancer therapies. At the core of its research and development strategy is the PD-1 x VEGF bispecific antibody, complemented by a range of novel antibody-drug conjugates (ADCs). This diversified pipeline underscores Crescent’s commitment to leveraging established pharmacological principles to create transformative treatments aimed at various solid tumors.
Continuously paving the path to innovative oncology solutions, Crescent is focused on rapidly advancing its therapies, whether used individually or in combination regimens, providing fresh hope for patients facing challenging diagnoses.
Contact Information
For media inquiries, please reach out to Amy Reilly, the Chief Communications Officer at Crescent Biopharma, via email at amy.reilly@crescentbiopharma.com or call at 617-465-0586.
Frequently Asked Questions
What is the purpose of Crescent Biopharma's upcoming presentations?
The presentations aim to engage with investors, share insights about the company's developments, and promote its innovative cancer therapies.
When is Crescent Biopharma scheduled to present at the Guggenheim conference?
Crescent Biopharma is scheduled to present at the Guggenheim 2nd Annual Healthcare Innovation Conference on November 11 at 8:00 a.m. ET.
How can investors access the presentations?
Investors can tune into live webcasts of the presentations on Crescent's official website, with replays available for 90 days.
What is Crescent Biopharma’s main focus in oncology?
The company specializes in developing therapies that target solid tumors through innovative approaches, including bispecific antibodies and antibody-drug conjugates.
Who can be contacted for media inquiries at Crescent Biopharma?
Amy Reilly, the Chief Communications Officer, is the point of contact for media inquiries at Crescent Biopharma.